Literature DB >> 3987628

Prolactin metabolic clearance and resistance to dopaminergic suppression in acute uremia.

T M McKenna, P D Woolf.   

Abstract

A nephrectomized rat model was developed to examine PRL resistance to dopaminergic suppression, which is frequently present in humans with renal insufficiency. The MCR and the response of PRL to a dopamine (DA) infusion (0.4 microgram/kg . min) were measured in 24-h totally nephrectomized (TN) and sham-nephrectomized (SN) rats concurrently treated with alpha-methyl-p-tyrosine (AMPT), an inhibitor of DA synthesis. TN rats became significantly hyperprolactinemic within 1 day [36.2 +/- 7.1 vs. 18.5 +/- 2.5 (+/- SE) ng/ml; P less than 0.05]. SN and TN rats responded to AMPT with significant and sustained 3- and 5.5-fold increases in PRL, which DA reduced by 85% and 24%, respectively. Total nephrectomy decreased the PRL MCR by 58% (TN, 0.51 +/- 0.03; SN, 1.22 +/- 0.13 ml/min; P less than 0.001) and significantly increased the PRL secretion rate (TN, 79 +/- 10; SN, 37 +/- 8 ng/min; P less than 0.01). In the absence of DA infusion, AMPT reduced plasma DA to undetectable levels, while the median eminence DA contents in TN and SN rats were reduced to similar levels. Our data suggest that the totally nephrectomized rat is a suitable model to study PRL resistance to dopaminergic suppression, and that because DA does not cross the blood-brain barrier, the defect in uremia probably occurs at the level of the lactotroph.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987628     DOI: 10.1210/endo-116-5-2003

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  3 in total

1.  Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis.

Authors:  Joan C Lo; Gerald J Beck; George A Kaysen; Christopher T Chan; Alan S Kliger; Michael V Rocco; Glenn M Chertow
Journal:  Hemodial Int       Date:  2016-10-23       Impact factor: 1.812

2.  Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD.

Authors:  Juan Jesús Carrero; John Kyriazis; Alper Sonmez; Ioannis Tzanakis; Abdul Rashid Qureshi; Peter Stenvinkel; Mutlu Saglam; Kostas Stylianou; Halil Yaman; Abdullah Taslipinar; Abdulgaffar Vural; Mahmut Gok; Mujdat Yenicesu; Eugene Daphnis; Mahmut Ilker Yilmaz
Journal:  Clin J Am Soc Nephrol       Date:  2011-12-22       Impact factor: 8.237

3.  Testosterone and gonadotropins but not SHBG vary with CKD stages in young and middle aged men.

Authors:  Britta Hylander; Mikael Lehtihet
Journal:  Basic Clin Androl       Date:  2015-12-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.